Control of breathing and neonatal apnea.
Great strides have been made in our understanding of developmental respiratory neurobiology. A clear picture is, therefore, emerging of the physiological mechanisms that underlie apnea of prematurity. The ventral surface of the medulla and adjacent areas play a key integrative function for central CO2 chemosensitivity and modulation of afferent inputs from peripheral chemoreceptors and laryngeal afferents. Maturational change in medullary neurotransmitter function appears to contribute to the physiological events that characterize apnea of prematurity. Despite this greater scientific insight, therapeutic strategies for neonatal apnea have changed little in 30 years. Xanthine therapy and continuous positive airway pressure remain the mainstay of therapy while other therapeutic approaches have been inadequately studied. Our understanding of a possible relationship between the triad of apnea, bradycardia and desaturation, and impaired neurodevelopmental outcome is also limited. These are all issues that need our attention if optimal therapy and outcome are to be provided for preterm infants with immature respiratory control.
Division of Neonatology, Department of Pediatrics, Case Western Reserve University, OH 44106 , USA. rxm6@cwru.edu
Richard J
RJ
Martin
Jalal M
JM
Abu-Shaweesh
D001049:Apnea / Q000503:physiopathology* / Q000628:therapy; D001919:Bradycardia / Q000503:physiopathology; D045422:Continuous Positive Airway Pressure; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000503:physiopathology* / Q000628:therapy; D014970:Xanthines / Q000627:therapeutic use
D014970:Xanthines; C008514:methylxanthine